3.4.21.110	medicine	acts as a potential invasin of group A streptococcus and promotes invasion independent of fibronectin	673973	
3.4.21.110	medicine	encapsulated C5a peptidase elicites significant immune responses and protection against group B streptococci challenge. C5a peptidase microsphere encapsulation has potential as a group B streptococci vaccine	684315	
3.4.21.110	medicine	encapsulated C5a peptidase elicits significant immune responses and protection against a group B Streptococcus challenge. C5a peptidase poly(lactide-coglycolide) microsphere encapsulation has potential as a group B Streptococcus vaccine	717065	
3.4.21.110	medicine	fibronectin adhesin activity of scpB plays a role in virulence	-, 687071	
3.4.21.110	medicine	immunization with C5a peptidase protein from either group A or group B streptococci provides protection against group A streptococcus infections in mice, moreover, mice immunized with antibodies directed against protein from group B streptococci also cleared streptococci from their lungs more efficiently than those immunized with tetanus toxoid	677242	
3.4.21.110	medicine	inactivates recombinant chemotaxin C5a by destroying its capacity to interact with the C5a receptor on human polymorphonuclear leukocytes	671820	
3.4.21.110	medicine	inactive mutant H193A elicits high titers of antigen-specific IgG1 antibodies and robust T cell-mediated immunities in mice showing potential as a Streptococcus vaccine. Cconjugating the trisaccharide repeating unit of Streptococcus polysaccharide with mutant H193A converts the nonimmunogenic oligosaccharide into a highly active and T cell-dependent antigen	755385	
3.4.21.110	medicine	increased anti-SCPA IgG levels in rheumatic fever, rheumatic heart disease and acute glomerulo nephritis cases. The rise of anti-SCPA IgG observed in patients is irrespective of different emm types of group A streptococci strains isolated from these patients. Indian females show higher concentration of anti-SCPA antibodies than male patients. Anti-SCPA IgG1 and anti-SCPA IgG3 are the predominant subclasses of anti-SCPA antibody and clearly distinguish individuals with acute rheumatic fever from those free of streptococcal disease	687103	
3.4.21.110	medicine	intranasal immunization with SCPA prevents colonization and infection of human tonsils, thereby eliminating potential reservoirs that maintain endemic disease	673982	
3.4.21.110	medicine	SCPA is highly immunogenic in children infected with group A streptococcal pharyngitis	673974	
3.4.21.110	medicine	the enzyme can be useful for development of subunit vaccine against the pathogen Streptococcus zooepidemicus	-, 732903	
3.4.21.110	medicine	the enzyme is used for vaccine development against group B Streptococcus	717499	
3.4.21.110	additional information	greatly reduces ability to bind to receptors of polymorphonuclear leukocytes as compared with native C5a, inactivation is temperature dependent, mediates a small decrease in the molecular weight of C5adesArg and a six-residue peptide in inactivated C5a is lost	676910	
3.4.21.110	additional information	ScpA and the multifunctional protein streptococcal plasmin receptor/surface dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase are both necessary for the cleavage of C5a on the bacterial surface	-, 674559	
3.4.21.110	additional information	streptococcal C5a peptidase binding to integrins by the Arg-Gly-Asp motifs may stabilize conformational changes required for substrate binding	676783